Dynamics between insight and medication adherence in first-episode psychosis: Study of 3-year trajectories.
First-episode psychosis
insight
medication adherence
specialized early psychosis program
Journal
European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820
Informations de publication
Date de publication:
15 08 2022
15 08 2022
Historique:
pubmed:
16
8
2022
medline:
9
9
2022
entrez:
15
8
2022
Statut:
epublish
Résumé
While specialized early intervention programs represent the gold standard in terms of optimal management of first-episode psychosis (FEP), poor medication adherence remains a predominant unmet need in the treatment of psychosis. In this regard, an interaction between insight and adherence in FEP patients has been hypothesized but has been challenged by multiple pitfalls. Latent profile analysis and trajectory modeling techniques were used to evaluate insight and adherence of 331 FEP patients engaged at the beginning, middle, and end of a 3-year specialized early psychosis program. A Bayesian model comparison approach was used to compare scores of clinical, functional, and socioeconomic outcomes at the end point of the study. Nearly one-third of the patients maintain a high level of insight and adherence during the entire program. At the end of the 3-year follow-up, more than three-quarters of patients are considered adherent to their medication. Patients with low levels of insight and adherence at the beginning of the program improve first in terms of adherence and then of insight. Furthermore, patients with high levels of insight and adherence are most likely to reach functional recovery and to experience an increase in environmental quality of life. Latent FEP subpopulations can be identified based on insight and adherence. Medication adherence was the first variable to improve, but a gain in insight possibly plays a role in the reinforcement of adherence.
Sections du résumé
BACKGROUND
While specialized early intervention programs represent the gold standard in terms of optimal management of first-episode psychosis (FEP), poor medication adherence remains a predominant unmet need in the treatment of psychosis. In this regard, an interaction between insight and adherence in FEP patients has been hypothesized but has been challenged by multiple pitfalls.
METHODS
Latent profile analysis and trajectory modeling techniques were used to evaluate insight and adherence of 331 FEP patients engaged at the beginning, middle, and end of a 3-year specialized early psychosis program. A Bayesian model comparison approach was used to compare scores of clinical, functional, and socioeconomic outcomes at the end point of the study.
RESULTS
Nearly one-third of the patients maintain a high level of insight and adherence during the entire program. At the end of the 3-year follow-up, more than three-quarters of patients are considered adherent to their medication. Patients with low levels of insight and adherence at the beginning of the program improve first in terms of adherence and then of insight. Furthermore, patients with high levels of insight and adherence are most likely to reach functional recovery and to experience an increase in environmental quality of life.
CONCLUSIONS
Latent FEP subpopulations can be identified based on insight and adherence. Medication adherence was the first variable to improve, but a gain in insight possibly plays a role in the reinforcement of adherence.
Identifiants
pubmed: 35968709
doi: 10.1192/j.eurpsy.2022.2305
pii: S0924933822023057
pmc: PMC9486827
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e49Références
Schizophr Bull. 2009 Mar;35(2):336-46
pubmed: 18586692
Psychiatry Res. 2018 Jun;264:151-154
pubmed: 29631247
J Nerv Ment Dis. 1996 Nov;184(11):653-9
pubmed: 8955677
J Clin Psychiatry. 2006;67 Suppl 5:3-8
pubmed: 16822090
Compr Psychiatry. 1997 Sep-Oct;38(5):283-8
pubmed: 9298321
J Clin Psychiatry. 2004 Feb;65(2):211-6
pubmed: 15003075
J Psychiatr Res. 2011 Jun;45(6):763-9
pubmed: 21106207
J Clin Psychiatry. 2010;71 Suppl 2:20-6
pubmed: 21190649
J Clin Psychiatry. 2003 Nov;64(11):1308-15
pubmed: 14658944
J Clin Psychopharmacol. 2010 Oct;30(5):565-72
pubmed: 20814327
Aust N Z J Psychiatry. 2016 May;50(5):410-72
pubmed: 27106681
N Engl J Med. 2005 Sep 22;353(12):1209-23
pubmed: 16172203
Early Interv Psychiatry. 2013 Aug;7(3):322-8
pubmed: 23445318
Schizophr Res. 2002 Oct 1;57(2-3):209-19
pubmed: 12223252
Acta Psychiatr Scand. 2000 Sep;102(3):203-10
pubmed: 11008856
Encephale. 1998 Jul-Aug;24(4):315-23
pubmed: 9809236
J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-8
pubmed: 19686636
Br J Psychiatry Suppl. 1998;172(33):53-9
pubmed: 9764127
Eur Psychiatry. 2012 Jan;27(1):43-9
pubmed: 20813506
Acta Psychiatr Scand. 2002 Oct;106(4):286-90
pubmed: 12225495
Schizophr Bull. 2011 Jan;37(1):38-51
pubmed: 20884756
Indian J Psychiatry. 2019;61(4):342-346
pubmed: 31391636
Am J Psychiatry. 2011 Jun;168(6):603-9
pubmed: 21362741
Eur Psychiatry. 2001 Aug;16(5):293-8
pubmed: 11514132
Eur J Clin Pharmacol. 2019 Oct;75(10):1421-1430
pubmed: 31218371
Schizophr Bull. 1982;8(3):470-84
pubmed: 7134891
Eur Psychiatry. 2017 Jan;39:73-79
pubmed: 27992809
Psychiatry Res. 2015 Aug 30;228(3):680-7
pubmed: 26099660
Psychiatry Clin Neurosci. 2005 Aug;59(4):403-9
pubmed: 16048445
Soc Sci Med. 1995 Nov;41(10):1403-9
pubmed: 8560308
Schizophr Res. 2020 Jan;215:17-24
pubmed: 31767511
West J Nurs Res. 2003 Feb;25(1):57-74
pubmed: 12584964
Am J Psychiatry. 2000 Feb;157(2):220-8
pubmed: 10671390
J Nerv Ment Dis. 1989 Jan;177(1):43-7
pubmed: 2562850
Ann Gen Psychiatry. 2020 Oct 3;19:58
pubmed: 33024446
Braz J Psychiatry. 2015 Apr-Jun;37(2):168-76
pubmed: 25946398
Arch Gen Psychiatry. 1990 Mar;47(3):228-36
pubmed: 1968329
J Clin Psychiatry. 2002 Oct;63(10):892-909
pubmed: 12416599
Arch Gen Psychiatry. 1998 Jan;55(1):49-55
pubmed: 9435760
Psychiatry Res. 2017 Nov;257:315-321
pubmed: 28800510
Acta Psychiatr Scand. 2013 Jan;127(1):23-33
pubmed: 22900964
Psychiatry Res. 2014 Dec 30;220(3):1084-9
pubmed: 25246410
Schizophr Bull. 1991;17(1):113-32
pubmed: 2047782
Schizophr Res. 2005 Sep 1;77(1):99-104
pubmed: 16005389
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
CNS Drugs. 2020 Jun;34(6):579-598
pubmed: 32219681
Am J Psychiatry. 2005 Mar;162(3):441-9
pubmed: 15741458
Schizophr Res. 2016 Jul;174(1-3):144-149
pubmed: 27050476
Neuropsychiatr Dis Treat. 2020 Mar 23;16:781-787
pubmed: 32256074
Schizophr Res. 2020 Jan;215:61-65
pubmed: 31780343
J Psychiatr Res. 2012 Aug;46(8):1099-105
pubmed: 22721546
Int J Law Psychiatry. 2019 Nov - Dec;67:101512
pubmed: 31785727
J Psychiatr Pract. 2008 Sep;14(5):289-300
pubmed: 18832960
Eur Psychiatry. 2006 Jan;21(1):29-33
pubmed: 16460918
Pharmacopsychiatry. 2022 Apr 25;:
pubmed: 35468642
Front Neurosci. 2020 Oct 09;14:531763
pubmed: 33162877
Eur Arch Psychiatry Clin Neurosci. 2021 Dec;271(8):1415-1424
pubmed: 33169212
Schizophr Res. 2017 Jan;179:50-56
pubmed: 27745754
Schizophr Bull. 2015 May;41(3):584-96
pubmed: 25750247
J Nerv Ment Dis. 2014 Jan;202(1):25-9
pubmed: 24375208
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216